The role of the serum IL-33/sST2 axis and inflammatory cytokines in chronic obstructive pulmonary disease

Journal of Interferon and Cytokine Research

Volumn 34, Issue 3, 2014, Pages 162-168

  Tang, Ying ^a   Guan, Yinghui ^a   Liu, Yang ^a   Sun, Jingting ^a   Xu, Lijun ^a   Jiang, Yanfang ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN; PROTEIN ST2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AIRWAY RESISTANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COR PULMONALE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKINS; LUNG; MALE; MIDDLE AGED; MYOCARDIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY HEART DISEASE; RECEPTORS, CELL SURFACE;

EID: 84895873165     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0063     Document Type: Article

References (43)

1. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, Liew FY. 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 16:708-712
2. Arshad MI, Rauch M, L'helgoualc'h A, Julia V, Leite-de-Moraes MC, Lucas-Clerc C, Piquet-Pellorce C, Samson M. 2011. NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis. Eur J Immunol 41:2341-2348
3. Barceló B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, Agustí AGN. 2006. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 145(3):474-479
4. Barczyk A, Pierzcha1a W, Kon OM, Cosio B, Adcock IM, Barnes PJ. 2006. Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 117(6):1484-1492
5. Barnes PJ. 2007. Chronic obstructive pulmonary disease: A growing but neglected epidemic. PLoS Med 4: E112
6. Barnes PJ. 2008. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183-192
7. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, Gombert JM, Schneider E, Dy M, Gourdy P, Girard JP, Herbelin A. 2009. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-g production. Eur J Immunol 39:1046-1055
8. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. 2007. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551-2555
9. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH. 2007. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27:461-466
10. Chung KF. 2001. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 34:50s-59s.
11. Couper KN, Blount DG, Riley EM. 2008. IL-10: The Master Regulator of Immunity to Infection. J Immunol 180(9):5771-5777
12. Di Francia M, Barbier D, Mege JL, Orehek J. 1994. Tumor necrosis factor-A levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150:1453-1455
13. Dodge IL, Carr MW, Cernadas M, Brenner MB. 2003. IL-6 Production by Pulmonary Dendritic Cells Impedes Th1 Immune Responses. J Immunol 170(9):4457-4464
14. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ. 2001. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:1414-1418
15. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, Kheradmand F. 2004. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 1:75-83
16. Hayakawa H, Hayakawa M, Kume A, Tominaga S. 2007. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282:26369-26380
17. Hong SC, Lee SH. 2010. Role of Th17 Cell and autoimmunity in chronic obstructive pulmonary disease. Immune Netw 10(4): 109-114
18. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. 2008. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 180:2443-2449
19. Keatings VM, Collins PD, Scott DM, Barnes PJ. 1996. Differences in interleukin-8 and tumor necrosis factor-A in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Resp Crit Care Med 153:530-534
20. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. 2007. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 37:2779-2786
21. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, Komai-Koma M, Pitman N, Li Y, Niedbala W. 2008. IL-33 induces antigen specific IL-5 + T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 181:4780-4790
22. Kuschner WG, DAlessandro A, Wong H, Blanc PD. 1996. Dosedependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 9:1989-1994
23. Liew FY, Pitman NI, McInnes IB. 2010. Disease-Associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol 10:103-110
24. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. 2000. Balance of matrix metalloprotease-9 andtissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers: Regulation by interleukin-10. Am J Respir Crit Care Med 162:1355-1360
25. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. 2006. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 367:1747-1757
26. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S, De Waal Malefyt R. 2011. Endogenous IL-33 enhances Th2 cytokine production and Tcell responses duringallergic airway inflammation. Int Immunol 23:307-315
27. Mannino DM, Buist AS. 2007. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 370:765-773
28. Marvie P, Lisbonne M, L'helgoualc'h A, Rauch M, Turlin B, Preisser L, Bourd-Boittin K, Theret N, Gascan H, Piquet-Pellorce C, Samson M. 2010. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 14:1726-1739
29. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. 2005. Standardisation of spirometry. Eur Respir J 26(2):319-338
30. Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J, Lowe L, Chen R, Shivraj L, Agadir A, Campos R, Ernst D, Gaur A. 2004. Cytometric bead array: A multiplexed assay platform with applications in various areas of biology. Clin Immunol 110:252-266
31. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. 2007. Profiling serum biomarkers in patients with COPD: Associations with clinical parameters. Thorax 62:595-596
32. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, vanWeel C, Zielinski J. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit CareMed 176(6):532-555
33. Sanada S, Hakuno D, Higgins L J, Schreiter E R, McKenzie A N, Lee R T. 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117:1538-1549
34. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-Associated cytokines. Immunity 23(5):479-490
35. Schols AM, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM. 1996. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51:819-824
36. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. 2008. IL-33 amplifies both Th1-And Th2-Type responses through its activity on human basophils, allergenreactive Th2 cells, iNKT and NK cells. Int Immunol 20:1019-1030
37. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, Tominaga S. 2001. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 285:1377-1383
38. Tárnok A, Hambsch J, Chen R, Varro R. 2003. Cytometric bead array to measure six cytokines in twenty-five microliters of serum. Clin Chem 49:1000-1002
39. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187(4):347-365
40. Volarevic V, Mitrovic M, Milovanovic M, Zelen I, Nikolic I, Mitrovic S, Pejnovic N, Arsenijevic N, Lukic ML. 2012. Protective Role of IL-33/ST2 Axis in Con A-Induced Hepatitis. J Hepatol 56(1):26-33
41. Walzl G, Matthews S, Kendall S, Gutierrez-Ramos JC, Coyle AJ, Openshaw PJ, Hussell T. 2003. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. J Exp Med 2001; 193:785-792
42. Weitzenblum E. 2003. Chronic cor pulmonale. Heart 89(2):225-230
43. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. 1998. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101(2):311-320